Company / Current Assets
Annovis Bio, Inc. Current Assets History
FY2020-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$10.2M
FY2023
5-year range
$10.2M / $46.0M
FY2020-FY2023
Trend
-71.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $46M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2023 with a 3-year CAGR of +7.9%.
Declined from $46M to $10M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +7.9%, indicating consistent growth.
- In FY2023, current assets decreased 71.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $10.2M | -71.7% |
| FY2022 | $36.0M | -21.7% |
| FY2021 | $46.0M | +466.6% |
| FY2020 | $8.1M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026